10 Stocks Shaking the Market

Recs

23

Some stocks are one-hit wonders that make a big splash when they first appear and then quickly fizzling into obscurity. But for other stocks, that initial big move is only a preview for even bigger and better gains to come.

Today, we've compiled 10 stocks that made some of the biggest upward moves over the past month. We'll then pair that list with the ratings issued by our Motley Fool CAPS community. The higher each stock's rating, the greater CAPS members' faith in that company's ability to keep on beating the market.

Stock

30-Day  % Change

CAPS Rating (Out of 5)

Human Genome Sciences

455%

*

Dana Holding

236%

**

KKR Financial (NYSE: KFN)

211%

***

Inovio Biomedical (AMEX: INO)

176%

*

Select Comfort (Nasdaq: SCSS)

184%

***

BioCryst Pharmaceuticals (Nasdaq: BCRX)

131%

*

Gannett

125%

**

China Green Agriculture (NYSE: CGA)

71%

****

Teck Resources (NYSE: TCK)

60%

****

Intuitive Surgical (Nasdaq: ISRG)

53%

****

Even as the markets have regained their winning ways, they haven't kept up with the pace of the movers and shakers of recent weeks. Pharmaceuticals and biotechs seem to rule the roost these days, with half of the companies on our list coming from those sectors, so let's see why the CAPS community thinks some of them might outperform the market.

A mighty temblor
Buy low, sell high. That's the mantra of most investors, but sometimes it's hard to practice. China's sovereign fund seems to have gotten it down to a science these days, though, as evidenced by its latest foray into the depressed commodities market. The big 17% equity stake it bought in Teck Resources gives it a piece of a top miner with assets in strategic resources such as zinc, metallurgical coal, copper, and gold.

That investment also allows Teck to meet its coming debt maturities and was a key driver behind the miner's recent ascent. An easing debt picture and improving pricing environment for commodities mean a stronger Teck in the future, and investors have been jumping on the rail cart to push shares higher.

CAPS member oyramnairb foresees substantial changes in the energy industry resulting in a charged atmosphere for growth.

Identical situation as Anglo American Plc (AAUK). This company will outperform the S&P because over the next twenty years energy and electricity will go through more changes than they did in the last 100 years. Electricity and batteries are still in [their] infancy. Any company that mines materials (copper, etc) that are used in electrical applications will see explosive growth over the next several years. It is a shame that Nautilus Minerals is not available through this service, it will also dramatically increase in value.

A prescription for crisis
In June, the World Health Organization announced that we were in the grips of a mighty swine flu pandemic and raised the warning alert to the highest "Phase 6" level. Stoked by the fears of a global calamity, shares of biotechs and pharmaceuticals developing vaccines for the H1N1 virus were bolstered by the hysteria.

BioCryst Pharmaceuticals got a particularly good dose of exuberance mid-last month, when it reported that its drug peramivir met the testing goals in two late-stage studies. After this news was released with an adjoining statement that the FDA is reviewing peramivir for emergency approval in the event of a swine flu outbreak, BioCryst's shares soared.

For some investors, though, rational thought is getting swept away as medical professionals up the urgency of their dire warnings. CAPS member UltraLong says BioCryst has failed to live up to its potential in the past and is doubtful that things will be any better this time around.

Peramivir [didn't] get approved to treat the 2002 flu strain, it wasn't good enough for the 2007 flu strain, and its only modestly effective for the swine flu which I SWEAR is less virulent than letting the elderly drive.

We have seen a 1200% run from the lows on the prospects that this might get government approval (after nearly 9 years). They have enough cash to run operations for 19-20 more months before they'll be hitting the unemployment line. Revenues are falling again, the one trick pony has shown its true colors ... again.

Shake, rattle, and roll
With these stocks shaking the market this past month, it pays to start your own research on them at Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made -- all from a stock's CAPS page.

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

Fool contributor Rich Duprey has no financial position in any of the stocks mentioned in this article. You can see his holdings. Intuitive Surgical is a Motley Fool Rule Breakers selection. China Green Agriculture is a Motley Fool Global Gains recommendation. Try any of our Foolish newsletter services free for 30 days. You can shake, rattle, and roll The Motley Fool's disclosure policy, but it still won't break.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 05, 2009, at 8:43 PM, djr474 wrote:

    Until very recently we weren't able to recommend SCSS which makes the CAP rating immaterial.

  • Report this Comment On August 06, 2009, at 6:23 AM, josephded wrote:

    Ultralog is obviously a FOOL because the facts he is relying on are totally incorrect. Biocryst has an abundancy of data which proves the "antiviral" Peramivir is a success as confirmed by the most recent Stage 3 clinical trial results by Asian partners Shionogi and Green Cross. IT WOULD BE HELPFUL TO READERS AND INVESTORS OF FOOL COMMENTS TO HAVE ALL THE TRUE AND RELEVANT FACTS PRESENTED. ULTRALONGS COMMENTS SHOULD BE ERASED. PLEASE SEE THE ATTACHED LINK ADVISING OF PHASE 3 CLINICAL RESULTS FOR PERAMIVIR. http://www.pharmaceuticalonline.com/article.mvc/BioCryst-Pha...

    Safe Bet - Biocryst (BCRX) Stock trade in $20 to

  • Report this Comment On August 11, 2009, at 8:49 AM, clawmann wrote:

    I can only provide my strongest support to what josephded has written.

  • Report this Comment On August 24, 2009, at 5:09 PM, clawmann wrote:

    The White House Science Advisors issued a report today urging FDA to speed up approval of peramivir.

    You can look it up.

    Next big step is the Emergency Use Authorization with a follow on order from the FDA of circa $400 million.

    Under Title VIII of the FY2009 Supplemental Appropriations Legislation, $5.8 billion has been made available in a contingency fund for flu preparedness. Obama and HHS need to tell Congress exactly what they are spending the money on 15 days prior to expenditure.

    I see the report issued today as the precondition for the submissions to Congress required by the supplemental appropriations legislation. Also, the $5.8 billion is a continuing appropriation, i.e. does not expire on September 30 (end of FY2009).

    The EUA is coming. As is the $400 million stockpile order.

    $20 by end of October. Easy.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 958315, ~/Articles/ArticleHandler.aspx, 12/3/2009 10:40:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Fool Search: Be GM's Next CEO!

By The Motley Fool

Fool Search: Be GM's Next CEO!

Related Tickers

12/3/2009 10:01 AM
KFN $5.47 Up +0.03 +0.55%
KKR Financial Hold… CAPS Rating: **
INO $1.39 Down -0.04 -2.80%
Inovio Biomedical… CAPS Rating: *
SCSS $4.77 Up +0.01 +0.21%
Select Comfort Cor… CAPS Rating: ***
ISRG $290.58 Up +2.94 +1.02%
Intuitive Surgical… CAPS Rating: ****
BCRX $8.00 Down -0.15 -1.84%
BioCryst Pharmaceu… CAPS Rating: *
TCK $35.40 Down -0.72 -1.99%
Teck Resources Lim… CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Due diligence: Due diligence is the research usually after a purchase to insure that the assets are as expected and properly valued.

Want to learn more or edit this definition?
Click here to read more!